Sign In
Buy AIM
$0.732
-0.0947 (-11.46%)
At Close: Jun 03, 2026
European Metals jumps 13% as AIM re-listing confirmed
09:34am, Tuesday, 30'th Apr 2024
European Metals Holdings jumped more than 13% seemingly on confirmation its switch of domicile from the British Virgin Islands is progressing with the forms submitted for it to become an Australia-bas
OCALA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has taken an essential step forward in testing the co
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
08:45am, Thursday, 25'th Apr 2024
OCALA, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Compan
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
08:45am, Thursday, 18'th Apr 2024
OCALA, Fla., April 18, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Compan
Union Jack Oil says Wressle continues to beat forecast and give robust revenue
03:11am, Wednesday, 17'th Apr 2024
Union Jack Oil PLC (AIM:UJO, OTCQB:UJOGF) executive chair David Bramhill told investors the Wressle field continues to deliver robust revenues, bolstering the AIM-quoted producer's strong balance shee
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
08:55am, Monday, 15'th Apr 2024
OCALA, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced that Charles Lapp, MD, is joining the company to help lead its efforts to develop
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
11:00am, Thursday, 11'th Apr 2024
OCALA, Fla., April 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Compan
OCALA, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytr
AIM ImmunoTech Inc. (AIM) Q4 2023 Earnings Call Transcript
11:32am, Tuesday, 02'nd Apr 2024
AIM ImmunoTech Inc. (NYSE:AIM ) Q4 2023 Earnings Conference Call April 2, 2024 8:30 AM ET Company Participants Thomas Equels - Chief Executive Officer Dr. Christopher McAleer - Scientific Officer Conf
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
07:30am, Tuesday, 02'nd Apr 2024
Year marked by growing body of promising data demonstrating Ampligen's potential to address multiple high-value indications
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
08:05am, Thursday, 28'th Mar 2024
OCALA, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K.
Aimia Inc. (AIMFF) Q4 2023 Earnings Call Transcript
11:55am, Tuesday, 26'th Mar 2024
Aimia Inc. (AIMFF) Q4 2023 Earnings Call Transcript
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
09:05am, Tuesday, 26'th Mar 2024
OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to di
Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Data demonstrate compelling evidence of the immune-stimulatory properties linked t
Aimia, Inc. (AIMFF) Q3 2023 Earnings Call Transcript
02:20pm, Tuesday, 14'th Nov 2023
Aimia, Inc. (OTCPK:AIMFF) Q3 2023 Earnings Conference Call November 14, 2023 8:30 AM ET Company Participants Albert Matousek - IR Phil Mittleman - CEO Michael Lehmann - President Steve Leonard - CFO C
